Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients
NCT ID: NCT04597086
Last Updated: 2023-04-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
74 participants
INTERVENTIONAL
2020-09-14
2023-01-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aromatherapy and Essential Oils in Improving Insomnia and Other Symptoms in Patients With Newly Diagnosed Acute Leukemia Undergoing Chemotherapy
NCT02445378
Effect of Increased Light Exposure on Fatigue in Breast Cancer
NCT00478257
Light Therapy to Increase Energy in Adolescents and Young Adults Newly Diagnosed With Solid Tumors: A Pilot Study
NCT02429063
An Investigation of Light Therapy for Cancer-related Fatigue (The LITE Study)
NCT01780623
The Effects of Light Therapy to Treat Cancer-related Side Effects
NCT04418856
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To assess the efficacy of bright white light therapy (BWLT) on fatigue in patients diagnosed with leukemia during their hospitalization.
SECONDARY OBJECTIVES:
I. To assess the efficacy of BWLT on sleep disturbance in patients diagnosed with leukemia during their hospitalization.
I. To assess the efficacy of BWLT on anxiety in patients diagnosed with leukemia during their hospitalization.
III. To assess the efficacy of BWLT on depression in patients diagnosed with leukemia during their hospitalization.
IV. To assess the efficacy of BWLT on distress in patients diagnosed with leukemia during their hospitalization.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive BWLT over 30 minutes in addition to standard of care daily during hospital stay.
GROUP II: Patients receive standard of care during hospital stay.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I (BWLT, best practice)
Patients receive BWLT over 30 minutes in addition to standard of care daily during hospital stay.
Best Practice
Receive standard of care
Bright White Light Therapy
Receive BWLT
Survey Administration
Ancillary studies
Group II (standard of care)
Patients receive standard of care during hospital stay.
Best Practice
Receive standard of care
Survey Administration
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Best Practice
Receive standard of care
Bright White Light Therapy
Receive BWLT
Survey Administration
Ancillary studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* English speaking
* Able to comprehend and sign a consent form
* Able to read and complete surveys
* Alert and oriented
* Without BWLT for seven days prior to initiating the trial
Exclusion Criteria
* Iritis, uveitis, keratitis, cataract, glaucoma, macular degeneration, retinal detachment, or retinitis pigmentosa
* Diagnosed bipolar disorder
* Persons with pacemakers
* The manufacturer of the BWLT unit used for this study mentions the light unit contains magnets
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ohio State University Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shelly Brown
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shelly Brown, MS, APRN-CNS
Role: PRINCIPAL_INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
The Jamesline
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2020-07234
Identifier Type: REGISTRY
Identifier Source: secondary_id
OSU-20091
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.